NasdaqGS:EXELBiotechs
How Broad CABOMETYX PFS Benefit At Exelixis (EXEL) Has Changed Its Investment Story
Exelixis recently reported subgroup results from the phase 3 CABINET trial showing that CABOMETYX significantly improved progression-free survival versus placebo in previously treated patients with advanced neuroendocrine tumors, regardless of functional status.
Because CABOMETYX already has U.S. approval for pancreatic and extra-pancreatic neuroendocrine tumors, these ASCO 2026 data mainly strengthen the drug’s clinical profile and potential real-world uptake rather than opening an entirely...